When do I go to meet with FDA?
Ophthalmic Product Development Insights
Sorting Out the Stats from the Jaks
The 20th anniversary of a landmark scientific discovery provides
an opportunity to look into the future of ocular therapies.
Begin with the End in Mind
Ophthalmic Product Development Insights
Aciex Enters Into Collaborative Research Agreement with Portola to Develop Dual Syk/JAK Inhibitors for Ophthalmic Indications
Ora will provide clinical development and regulatory consulting services to the collaboration.
Pre-clinical models
Ora’s pre-clinical group is busy developing a number of animal models of ocular disease to use in early stages of the development and candidate drug screening process.
The Antimicrobial Evolution
With several new therapies in the pipeline, practitioners may soon have a
new arsenal of drugs to better treat ocular infections.
Prime Factors of Ocular Allergy
A guide to understanding the process known as allergen
priming, which plays a key role in allergic conjunctivitis.
Staying Local with Blepharitis Treatment
Ways to diagnose and categorize the disease, and thoughts on the best way to treat it when it occurs.
Of Biomes, Biofilm and The Ocular Surface
Knowing how bacteria grow and communicate may hold the
key to future treatments for ophthalmic infections.
Ora in India
Ocular therapeutics is a global business so it’s no surprise that current Ora projects include studies around the world.